Milestone Scientific Inc

Milestone Scientific Inc(MLSS)股票分析

$0.302

+0.003 (+0.97%)收盘时

Loading chart…
最高
0.329
开盘
0.310
成交量加权均价
0.31
成交量
90.06K
市值
52.51M
最低
0.300
成交额
27.95K
企业价值/息税折旧摊销前利润(TTM)
-6.33

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries.

AI 分析 of Milestone Scientific Inc (MLSS)

持有

Milestone Scientific Inc is currently trading at $0.302, which is significantly below its 52-week high of $0.58, indicating potential for recovery. However, the RSI is at 42.26, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 18.21, indicating that the stock may be overvalued based on future earnings expectations. The company has shown revenue growth of 22% year-over-year in Q2 2026, but it still faces challenges with declining gross margins and negative net income, which was -$1,059,332 in Q2 2026. The main risk is the declining gross margin, which fell to 66.55% in Q2 2026, indicating increasing costs that could impact profitability.

分析师评级(1)

上行空间 +231.13%
买入
1 买入
0 持有
0 卖出
当前: 0.30
最低
1.00
平均
1.00
最高
1.00

Benchmark

2025-11-20

目标价

$1

Speculative Buy

Benchmark

2024-11-20

目标价

$1.25

买入

Benchmark

2024-10-10

目标价

$1.25

买入

估值指标

Milestone Scientific Inc(MLSS)当前预期市盈率为 18.21,5 年平均预期市盈率为 -8.67。

预期市盈率

高估
5 年均值 P/E
-8.67
当前P/E
18.21
高估
4.93
低估
-22.27

预期 EV/EBITDA

低估
5 年均值 EV/EBITDA
-1.14
当前EV/EBITDA
-6.33
高估
1.51
低估
-3.79

预期市销率

低估
5 年均值 P/S
5.64
当前P/S
2.39
高估
8.30
低估
2.98

Alphio AI 对 MLSS 的价格情景

情景价格取自当年最后一个月度预测区间。概率为固定的模型权重(25 / 50 / 25),不构成保证。

乐

乐观

乐观 · 25%MLSS

$0.99

情景价格

基

基准

基准 · 50%MLSS

$0.88

情景价格

悲

悲观

悲观 · 25%MLSS

$0.85

情景价格

事件时间线

2026-09-29 (ET)

09:30:00

Milestone Scientific Drives Growth in CompuFlo Medical Business

2026-09-08 (ET)

17:30:00

Milestone Scientific Files $45M Mixed Securities Shelf

2026-07-01 (ET)

12:00:00

Markets Mixed as Semiconductor Stocks Slip

09:30:00

Company Reports 300% Revenue Growth in Q2

2026-05-14 (ET)

16:30:00

Dow Rises 370 Points as Markets Optimistic on US-China Talks

资讯

MLSS 常见问题 —— 由 Alphio AI 解答

Milestone Scientific Inc. is a biomedical technology company. The Company patents, designs, develops and commercializes diagnostic and therapeutic injection technologies and devices for medical and dental use. The Company operates through two segments: dental and medical. The Company has developed a computer-controlled anesthetic delivery device, its DPS Dynamic Pressure Sensing Technology System, to meet the needs of various subcutaneous drug delivery injections and fluid aspiration. Its device, using The Wand, a single-use disposable handpiece, is marketed in dentistry under the trademarks CompuDent and STA Single Tooth Anesthesia System, and is suitable for all dental procedures that require local anesthetic. The dental devices are sold in the United States, Canada and in over 41 other countries. In addition, the Company has obtained CE mark approval for certain medical devices, which can be marketed and sold in various European countries. It operates in the Healthcare sector (ORTHOPEDIC, PROSTHETIC & SURGICAL APPLIANCES & SUP industry).

Milestone Scientific Inc is currently trading at $0.302, which is significantly below its 52-week high of $0.58, indicating potential for recovery. However, the RSI is at 42.26, suggesting the stock is neither overbought nor oversold, and the forward P/E ratio is 18.21, indicating that the stock may be overvalued based on future earnings expectations. The company has shown revenue growth of 22% year-over-year in Q2 2026, but it still faces challenges with declining gross margins and negative net income, which was -$1,059,332 in Q2 2026. The main risk is the declining gross margin, which fell to 66.55% in Q2 2026, indicating increasing costs that could impact profitability.

1 analysts cover MLSS: 1 rate it Buy, 0 Hold and 0 Sell. The average price target is 1.00.

暂无帖子

注册或登录后参与讨论

相关文章

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

开始交易